ID   CLC4A_MOUSE             Reviewed;         238 AA.
AC   Q9QZ15; Q4VA33;
DT   15-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   03-AUG-2022, entry version 144.
DE   RecName: Full=C-type lectin domain family 4 member A;
DE   AltName: Full=C-type lectin superfamily member 6;
DE   AltName: Full=Dendritic cell immunoreceptor;
DE   AltName: CD_antigen=CD367;
GN   Name=Clec4a; Synonyms=Clec4a2, Clecsf6, Dcir;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lymph node;
RX   PubMed=10438934;
RA   Bates E.E.M., Fournier N., Garcia E., Valladeau J., Durand I., Pin J.-J.,
RA   Zurawski S.M., Patel S., Abrams J.S., Lebecque S., Garrone P., Saeland S.;
RT   "APCs express DCIR, a novel C-type lectin surface receptor containing an
RT   immunoreceptor tyrosine-based inhibitory motif.";
RL   J. Immunol. 163:1973-1983(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, MUTAGENESIS OF
RP   TYR-7, AND DOMAIN.
RC   STRAIN=BALB/cJ;
RX   PubMed=11841542; DOI=10.1046/j.0022-202x.2001.01633.x;
RA   Kanazawa N., Okazaki T., Nishimura H., Tashiro K., Inaba K., Miyachi Y.;
RT   "DCIR acts as an inhibitory receptor depending on its immunoreceptor
RT   tyrosine-based inhibitory motif.";
RL   J. Invest. Dermatol. 118:261-266(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Cerebellum;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Jaw, Limb, and Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
CC   -!- FUNCTION: May be involved in regulating immune reactivity. May play a
CC       role in modulating dendritic cells (DC) differentiation and/or
CC       maturation (By similarity). May be involved in the inhibition of B-
CC       cell-receptor-mediated calcium mobilization and protein tyrosine
CC       phosphorylation. {ECO:0000250, ECO:0000269|PubMed:11841542}.
CC   -!- FUNCTION: C-type lectin receptor that binds carbohydrates mannose and
CC       fucose but also weakly interacts with N-acetylglucosamine (GlcNAc) in a
CC       Ca(2+)-dependent manner. Involved in regulating immune reactivity. Once
CC       triggered by antigen, it is internalized by clathrin-dependent
CC       endocytosis and delivers its antigenic cargo into the antigen
CC       presentation pathway resulting in cross-priming of CD8(+) T cells. This
CC       cross-presentation and cross-priming are enhanced by TLR7 and TLR8
CC       agonists with increased expansion of the CD8(+) T cells, high
CC       production of IFNG and TNF with reduced levels of IL4, IL5 and IL13. In
CC       plasmacytoid dendritic cells, inhibits TLR9-mediated IFNA and TNF
CC       production (By similarity). May be involved via its ITIM motif
CC       (immunoreceptor tyrosine-based inhibitory motifs) in the inhibition of
CC       B-cell-receptor-mediated calcium mobilization and protein tyrosine
CC       phosphorylation (PubMed:11841542). {ECO:0000250|UniProtKB:Q9UMR7,
CC       ECO:0000269|PubMed:11841542}.
CC   -!- SUBUNIT: May interact with PTPN6 via its ITIM site.
CC       {ECO:0000250|UniProtKB:Q9UMR7}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type II
CC       membrane protein {ECO:0000250|UniProtKB:Q9UMR7}; Extracellular side
CC       {ECO:0000250|UniProtKB:Q9UMR7}.
CC   -!- TISSUE SPECIFICITY: Expressed in splenic antigen-presenting cells
CC       including B-cells, monocytes/macrophages, and dendritic cells (at
CC       protein level). Expressed in spleen and lymph node and slightly
CC       increased with dendritic cell maturation.
CC       {ECO:0000269|PubMed:11841542}.
CC   -!- DOMAIN: Contains 1 copy of a cytoplasmic motif that is referred to as
CC       the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is
CC       involved in modulation of cellular responses. The phosphorylated ITIM
CC       motif can bind the SH2 domain of several SH2-containing phosphatases.
CC       {ECO:0000269|PubMed:11841542}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=DCIR1;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_mou_Ctlect_160";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ133533; CAB57870.1; -; mRNA.
DR   EMBL; AF387099; AAM22402.1; -; mRNA.
DR   EMBL; AK049002; BAC33509.1; -; mRNA.
DR   EMBL; BC075729; AAH75729.1; -; mRNA.
DR   EMBL; BC096565; AAH96565.1; -; mRNA.
DR   CCDS; CCDS20510.1; -.
DR   RefSeq; NP_001163803.1; NM_001170332.1.
DR   RefSeq; NP_001163804.1; NM_001170333.1.
DR   RefSeq; NP_036129.1; NM_011999.4.
DR   AlphaFoldDB; Q9QZ15; -.
DR   SMR; Q9QZ15; -.
DR   STRING; 10090.ENSMUSP00000032248; -.
DR   GlyConnect; 2239; 1 N-Linked glycan (1 site).
DR   GlyGen; Q9QZ15; 3 sites, 1 N-linked glycan (1 site).
DR   iPTMnet; Q9QZ15; -.
DR   PhosphoSitePlus; Q9QZ15; -.
DR   MaxQB; Q9QZ15; -.
DR   PRIDE; Q9QZ15; -.
DR   DNASU; 26888; -.
DR   Ensembl; ENSMUST00000041779; ENSMUSP00000045781; ENSMUSG00000030148.
DR   Ensembl; ENSMUST00000161365; ENSMUSP00000124615; ENSMUSG00000030148.
DR   GeneID; 26888; -.
DR   KEGG; mmu:26888; -.
DR   UCSC; uc009dqa.1; mouse.
DR   CTD; 26888; -.
DR   MGI; MGI:1349412; Clec4a2.
DR   VEuPathDB; HostDB:ENSMUSG00000030148; -.
DR   eggNOG; KOG4297; Eukaryota.
DR   GeneTree; ENSGT00940000162867; -.
DR   HOGENOM; CLU_049894_7_5_1; -.
DR   InParanoid; Q9QZ15; -.
DR   OMA; MINSARG; -.
DR   OrthoDB; 1378771at2759; -.
DR   PhylomeDB; Q9QZ15; -.
DR   BioGRID-ORCS; 26888; 2 hits in 72 CRISPR screens.
DR   ChiTaRS; Clec4a2; mouse.
DR   PRO; PR:Q9QZ15; -.
DR   Proteomes; UP000000589; Chromosome 6.
DR   RNAct; Q9QZ15; protein.
DR   Bgee; ENSMUSG00000030148; Expressed in granulocyte and 112 other tissues.
DR   ExpressionAtlas; Q9QZ15; baseline and differential.
DR   Genevisible; Q9QZ15; MM.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; TAS:MGI.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; ISS:UniProtKB.
DR   GO; GO:0005537; F:mannose binding; ISS:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0061760; P:antifungal innate immune response; IBA:GO_Central.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; ISS:UniProtKB.
DR   GO; GO:0036037; P:CD8-positive, alpha-beta T cell activation; ISS:UniProtKB.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0001818; P:negative regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISS:UniProtKB.
DR   GO; GO:0002470; P:plasmacytoid dendritic cell antigen processing and presentation; ISS:UniProtKB.
DR   CDD; cd03590; CLECT_DC-SIGN_like; 1.
DR   Gene3D; 3.10.100.10; -; 1.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR033989; CD209-like_CTLD.
DR   InterPro; IPR016187; CTDL_fold.
DR   Pfam; PF00059; Lectin_C; 1.
DR   SMART; SM00034; CLECT; 1.
DR   SUPFAM; SSF56436; SSF56436; 1.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Calcium; Cell membrane; Disulfide bond; Glycoprotein;
KW   Immunity; Innate immunity; Lectin; Membrane; Metal-binding;
KW   Reference proteome; Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN           1..238
FT                   /note="C-type lectin domain family 4 member A"
FT                   /id="PRO_0000046613"
FT   TOPO_DOM        1..48
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        49..69
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        70..238
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          126..233
FT                   /note="C-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   MOTIF           5..10
FT                   /note="ITIM motif"
FT   BINDING         146
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         152
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         197..199
FT                   /ligand="alpha-D-mannopyranose"
FT                   /ligand_id="ChEBI:CHEBI:28729"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         197
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         199
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         203
FT                   /ligand="alpha-D-mannopyranose"
FT                   /ligand_id="ChEBI:CHEBI:28729"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         203
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         209..211
FT                   /ligand="N-acetyl-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:506227"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         219
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   BINDING         220
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UMR7"
FT   CARBOHYD        91
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        131
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        136
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        107..118
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DISULFID        137..231
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DISULFID        205..223
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   MUTAGEN         7
FT                   /note="Y->F: Loss of inhibition of B-cell calcium
FT                   mobilization."
FT                   /evidence="ECO:0000269|PubMed:11841542"
SQ   SEQUENCE   238 AA;  27323 MW;  2DB8AE0E11B18A56 CRC64;
     MASEITYAEV KFKNESNSLH TYSESPAAPR EKPIRDLRKP GSPSLLLTSL MLLLLLLAIT
     FLVAFIIYFQ KYSQLLEEKK AAKNIMHNEL NCTKSVSPME DKVWSCCPKD WRLFGSHCYL
     VPTVSSSASW NKSEENCSRM GAHLVVIQSQ EEQDFITGIL DTHAAYFIGL WDTGHRQWQW
     VDQTPYEESI TFWHNGEPSS GNEKCATIIY RWKTGWGWND ISCSLKQKSV CQMKKINL
//
